The Current State of Retatrutide Availability
Retatrutide is not available through standard pharmacies in the United States as of May 2026. The drug has not received FDA approval, and Eli Lilly has not announced a brand name or pricing for the eventual commercial product. The only legal access route is through Eli Lilly’s TRIUMPH clinical trials, which are enrolling at research centers across the country. For everyone else, the available supply comes from the grey market for research peptides.
Grey Market Vendors and Pricing
Research chemical vendors sell retatrutide as a lyophilized powder labeled “for research use only.” A 10 mg vial typically ranges from $60 to $120 depending on the vendor. A 20 mg vial ranges from $100 to $200. A 30 mg vial ranges from $150 to $300. Prices vary based on whether the vendor provides third-party Certificate of Analysis results, how recently the product was manufactured, and whether the vendor has established a reputation in the research peptide community.
How to Evaluate a Vendor
The grey market is unregulated, so the burden of quality assessment falls on the buyer. The most reliable indicator is a recent Certificate of Analysis from an independent laboratory showing both purity (target: 98% or higher) and identity confirmation via HPLC or mass spectrometry. Vendors that publish COAs transparently on their website are generally more trustworthy than those that do not. Community forums on Reddit and peptide discussion boards provide real-user reports on specific vendors, but individual experiences vary widely.
When Will Retatrutide Be Available Through Pharmacies?
Based on the current trial timeline, the earliest realistic FDA approval would be late 2027. The NDA submission is expected in late 2026 or early 2027, and standard FDA review takes 10 to 12 months. Once approved, retatrutide would be available by prescription through standard pharmacies, with pricing likely comparable to Zepbound (tirzepatide) at $800 to $1,200 per month before insurance.
Leave a Reply